Mitogen Activated Protein Kinases : Functions in Signal Transduction and Human Diseases
Mitogen-activated protein kinases (MAPK) are a large family of enzymes that function as signal transducers to regulate a diverse range of physiological responses. However, signaling via extracellular signal-regulated kinase (ERK), c-Jun amino terminal kinase (JNK), and p38 MAPK also underpin many di...
Saved in:
| HerausgeberIn: | |
|---|---|
| Sonstige: | |
| Year of Publication: | 2020 |
| Language: | English |
| Physical Description: | 1 electronic resource (276 p.) |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| LEADER | 04337nam-a2201297z--4500 | ||
|---|---|---|---|
| 001 | 993545482804498 | ||
| 005 | 20231214133454.0 | ||
| 006 | m o d | ||
| 007 | cr|mn|---annan | ||
| 008 | 202105s2020 xx |||||o ||| 0|eng d | ||
| 035 | |a (CKB)5400000000043620 | ||
| 035 | |a (oapen)https://directory.doabooks.org/handle/20.500.12854/68643 | ||
| 035 | |a (EXLCZ)995400000000043620 | ||
| 041 | 0 | |a eng | |
| 100 | 1 | |a Tikkanen, Ritva |4 edt | |
| 245 | 1 | 0 | |a Mitogen Activated Protein Kinases |b Functions in Signal Transduction and Human Diseases |
| 246 | |a Mitogen Activated Protein Kinases | ||
| 260 | |a Basel, Switzerland |b MDPI - Multidisciplinary Digital Publishing Institute |c 2020 | ||
| 300 | |a 1 electronic resource (276 p.) | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 520 | |a Mitogen-activated protein kinases (MAPK) are a large family of enzymes that function as signal transducers to regulate a diverse range of physiological responses. However, signaling via extracellular signal-regulated kinase (ERK), c-Jun amino terminal kinase (JNK), and p38 MAPK also underpin many disease processes. This Special Issue provides new insights into how MAPK signaling contributes to specific pathological processes across a range of conditions, including disorders of lung development, type 2 diabetes, proliferative skin diseases, cardiovascular diseases, and neurological diseases. | ||
| 546 | |a English | ||
| 650 | 7 | |a Research & information: general |2 bicssc | |
| 650 | 7 | |a Biology, life sciences |2 bicssc | |
| 653 | |a Rabdosia inflexa | ||
| 653 | |a inflammation | ||
| 653 | |a gastric ulcer | ||
| 653 | |a cytokines | ||
| 653 | |a MAPK | ||
| 653 | |a NF-κB | ||
| 653 | |a extracellular signal-regulated kinases 1/2 | ||
| 653 | |a hyperoxia | ||
| 653 | |a bronchopulmonary dysplasia | ||
| 653 | |a HPAECs | ||
| 653 | |a angiogenesis | ||
| 653 | |a cell cycle | ||
| 653 | |a SIRT1 | ||
| 653 | |a oxidative stress | ||
| 653 | |a psoriasis | ||
| 653 | |a antimicrobial peptide | ||
| 653 | |a cecropin A | ||
| 653 | |a tight junction protein | ||
| 653 | |a MEK/ERK signaling | ||
| 653 | |a porcine intestinal epithelial cell | ||
| 653 | |a extracellular signal-regulated kinase 5 (ERK5) | ||
| 653 | |a Kv4.2 | ||
| 653 | |a PC12 cells | ||
| 653 | |a infantile myofibromatosis | ||
| 653 | |a receptor tyrosine kinases | ||
| 653 | |a platelet-derived growth factor receptor | ||
| 653 | |a protein kinase inhibitors | ||
| 653 | |a sunitinib | ||
| 653 | |a erlotinib | ||
| 653 | |a FR180204 | ||
| 653 | |a U0126 | ||
| 653 | |a targeted therapy | ||
| 653 | |a apoptosis | ||
| 653 | |a ERK1/2 | ||
| 653 | |a JNKs | ||
| 653 | |a mitochondrial dysfunction | ||
| 653 | |a neurodegeneration | ||
| 653 | |a neuro-inflammation | ||
| 653 | |a p38 MAPKs | ||
| 653 | |a Parkinson's disease | ||
| 653 | |a mitogen-activated protein kinases (MAPKs) | ||
| 653 | |a MAPK kinetics | ||
| 653 | |a osteoclast differentiation | ||
| 653 | |a bone remodeling | ||
| 653 | |a DAPK | ||
| 653 | |a ERK | ||
| 653 | |a p38 | ||
| 653 | |a JNK | ||
| 653 | |a mitogen-activated protein kinase pathway (MAPK pathway) | ||
| 653 | |a protein tyrosine phosphatase interacting protein 51 (PTPIP51) | ||
| 653 | |a protein-protein interaction (PPI) | ||
| 653 | |a cancer signaling | ||
| 653 | |a SR | ||
| 653 | |a CR | ||
| 653 | |a Compatibility | ||
| 653 | |a T2DM | ||
| 653 | |a metabolic profiling | ||
| 653 | |a MAPK/PI3K/Akt signaling pathway | ||
| 653 | |a reactive oxygen species | ||
| 653 | |a PTPN6 | ||
| 653 | |a SRC | ||
| 653 | |a DOK4 | ||
| 653 | |a MKK4 | ||
| 653 | |a MKK7 | ||
| 653 | |a p53 | ||
| 653 | |a DUSP1 | ||
| 653 | |a SIRT2 | ||
| 653 | |a atherosclerosis | ||
| 653 | |a aortic valve sclerosis | ||
| 653 | |a aortic valve stenosis | ||
| 653 | |a naphthalimide-metal complex conjugates | ||
| 653 | |a N-heterocyclic carbene | ||
| 653 | |a mitochondria | ||
| 653 | |a ROS | ||
| 653 | |a p38 MAPK | ||
| 653 | |a cancer | ||
| 653 | |a FGF-induced signaling | ||
| 653 | |a FRS2 | ||
| 653 | |a phosphorylation | ||
| 653 | |a downregulation | ||
| 776 | |z 3-03928-070-8 | ||
| 776 | |z 3-03928-071-6 | ||
| 700 | 1 | |a Nikolic-Paterson, David |4 edt | |
| 700 | 1 | |a Tikkanen, Ritva |4 oth | |
| 700 | 1 | |a Nikolic-Paterson, David |4 oth | |
| 906 | |a BOOK | ||
| ADM | |b 2023-12-15 05:55:04 Europe/Vienna |f system |c marc21 |a 2022-04-04 09:22:53 Europe/Vienna |g false | ||
| AVE | |i DOAB Directory of Open Access Books |P DOAB Directory of Open Access Books |x https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5337927480004498&Force_direct=true |Z 5337927480004498 |b Available |8 5337927480004498 | ||